As the world’s second-largest healthcare market, China spends about $575 billion a year on the sector, roughly equivalent to Sweden’s GDP. But because of China’s large population, that translates into only $420 in per capita healthcare spending, just 4% of what an average American spends. This healthcare supply shortage is exacerbated by rising demand from wealthier Chinese who seek quality care, better insurance, and diverse services.
On the regulatory side, the Chinese government continues to reform the healthcare sector by allowing doctors to work
outside the public hospital system, encouraging the privatization of hospitals, and expanding public healthcare insurance to cover private hospitals.
The significant mismatch between supply and demand, coupled with policy changes to support the sector, have incentivized private investment to flock into areas ranging from advanced pharmaceuticals and medical devices to primary care clinics, elderly care, and insurance products.
Livzon Pharmaceutical Group is an integrated pharmaceutical manufacturer and distributor. The company makes drug preparations and active pharmaceutical ingredients, as well as diagnostic reagents and equipment. Its flagship products include nerve growth factor medicine, antidepressants, and ulcer and prostate drugs.
Jolywood Suzhou acquired an Italian solar backsheet maker, Filmcutter Advanced Materials S.P.A., for €4.4 million in 2015. Through a wholly-owned subsidiary in Hong Kong, the company in June 2016 acquired a 49% stake in a Japanese solar modules maker, Energy Gap Corporation, for $4.3 million.